At13148 is a Novel, Oral Multi-Agc Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity.
Yap, T.A., Walton, M.I., Grimshaw, K.M., Te Poele, R.H., Eve, P.D., Valenti, M.R., De Haven Brandon, A.K., Martins, V., Zetterlund, A., Heaton, S.P., Heinzmann, K., Jones, P.S., Feltell, R.E., Reule, M., Woodhead, S.J., Davies, T.G., Lyons, J.F., Raynaud, F.I., Eccles, S.A., Workman, P., Thompson, N.T., Garrett, M.D.(2012) Clin Cancer Res 18: 3912
- PubMed: 22781553 
- DOI: https://doi.org/10.1158/1078-0432.CCR-11-3313
- Primary Citation of Related Structures:  
4AXA - PubMed Abstract: 
Deregulated phosphatidylinositol 3-kinase pathway signaling through AGC kinases including AKT, p70S6 kinase, PKA, SGK and Rho kinase is a key driver of multiple cancers. The simultaneous inhibition of multiple AGC kinases may increase antitumor activity and minimize clinical resistance compared with a single pathway component.
Organizational Affiliation: 
Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton, United Kingdom.